Happy #MarathonMonday, Boston! Wishing all participants the best of luck! The #BostonMarathon is one of the hallmarks of our beloved Boston community. Let's stay #BostonStrong today and always.
Ikena Oncology
生物技术研究
Boston，Massachusetts 9,813 位关注者
Patient-directed oncology therapies across pathways relevant in tumor and immune cells
关于我们
Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables us to target specific patient populations that we believe are most likely to respond to treatment with our product candidates. We have assembled an experienced and well-respected team of drug hunters, translational researchers, clinicians and entrepreneurs drawn from many of the largest innovators in biotechnology, supported by top-tier investors and partners, as well as world-class advisors, to advance and broaden our portfolio of novel, patient-directed oncology therapies.
- 网站
-
https://www.ikenaoncology.com
Ikena Oncology的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Boston，Massachusetts
- 类型
- 上市公司
- 创立
- 2016
- 领域
- Targeted Oncology、cancer therapeutics development、small molecule drug design、cancer biology和translational science and biomarkers
地点
-
主要
获取路线
645 Summer Street
Suite 101
US，Massachusetts，Boston，02210
Ikena Oncology员工
动态
-
Ikena’s management team will present a corporate overview at the Stifel Financial Corp. 2024 Virtual Targeted Oncology Forum, taking place April 16-17. For more information and to register for the virtual webcast, visit: https://brnw.ch/21wIGym
-
-
Join us at the American Association for Cancer Research (AACR) 2024 Annual Meeting and check out our poster (#3296), highlighting our best-in-class MEK-RAF molecular glue, IK-595, and its potential as both a monotherapy and in combination. Click the link for more information and visit us on April 8 between 1:30pm-5pm PST: https://bit.ly/4abpxy0 #AACR2024 #AACR24
-
-
This #InternationalWomensDay, we celebrate the strength, resilience and outstanding achievements of women globally. We proudly support the advancement of women in #biotech and are particularly proud of the women making strides right here at Ikena. We remain steadfast in our commitment to shaping a future that is inclusive and equitable for all. #IWD2024 #InspireInclusion
-
-
We’re excited to welcome Dr. Caroline Germa on her first day as Ikena’s Chief Medical Officer. Dr. Germa is an accomplished senior executive and medical oncologist, bringing over 25 years of industry and drug development expertise. Read more here:?https://bit.ly/4bT7tdp
-
-
Our novel TEAD inhibitor, IK-930, was granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of epithelioid hemangioendothelioma (EHE). This decision marks a significant milestone, and we are eager to advance our program to benefit this patient population. Learn about our program here: https://brnw.ch/21wHpbH
-
-
Our Chief Executive Officer, Mark Manfredi, Ph.D., will join a #TargetedOncology panel at Cowen Inc. 44th Annual Health Care Conference taking place March 4-6, 2024. Ikena’s management team will also be holding one-on-one investor meetings at the conference. For registration details, click the link: https://brnw.ch/21wHmMN
-
-
As a clinical stage oncology company, Ikena remains steadfastly committed to developing our #TargetedOncology therapies to help patients suffering from cancers with high unmet medical need. Our focus is on advancing our lead clinical assets, IK-930 and IK-595, which we believe could drastically improve patient outcomes. Learn more on our website: https://brnw.ch/21wHboD
-
-
In case you missed it, the first cohort of patients in our Phase 1 study of IK-595, our novel MEK-CRAF molecular glue, has cleared the initial safety evaluation and we are moving forward in dose escalation! Learn more about our clinical development program by visiting our website: https://brnw.ch/21wGVVp
-
-
We are thrilled by the FDA's recent Orphan Drug Designation for IK-930 in treating EHE. This milestone is a testament to our dedication and the incredible support from The EHE Foundation and the patient community. Thank you for standing with us on our mission to potentially transform the lives of #cancer patients.
Breaking News! Ikena Oncology has shared that on December 14th, 2023, the Food and Drug Administration (FDA) granted Orphan Drug Designation to IK-930 for the treatment of epithelioid hemangioendothelioma (EHE). We are excited about this designation following initial positive data from the IK-930 Phase I clinical trial published in November 2023. What does this mean for EHE patients? Orphan Drug Designation for IK-930 gives us a strong signal that the development of the drug is on track. While we still have a long way to go, this is a positive step toward having an FDA-approved therapy to treat EHE. The FDA grants Orphan Drug Designation to incentivize companies like Ikena to continue the development of a drug for a small patient population. Ikena’s press release about initial positive data from the Phase I study of IK-930: https://lnkd.in/eXWgKsVE https://lnkd.in/ejdCiWsZ